Multicentre randomized clinical trial to investigate the cost‐effectiveness of an allogeneic single‐donor fibrin sealant after coronary artery bypass grafting (FIBER Study). Issue 11 (12th August 2015)

• Record Type: Journal Article
• Authors: Tavilla, G.; Bruggemans, E. F.; Gielen, C. L. I.; Brand, A.; van den Hout, W. B.; Klautz, R. J. M.; van Hilten, J. A.
• Is Part Of: British journal of surgery. Volume 102:Issue 11(2015:Nov.)
• Page Start: 1338
• Page End: 1347
• Publication Date: 2015-08-12
• Subjects: Surgery -- Periodicals; 617.005
• DOI: 10.1002/bjs.9877
• Languages: English
• ISSNs: 0007-1323

Abstract

<abstract abstract-type="main" id="bjs9877-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bjs9877-sec-0001" sec-type="section"> <title>Background</title> <p id="bjs9877-para-0001">Reduction of blood transfusion in cardiac surgery is an important target. The aim of this study was to investigate the cost‐effectiveness of the use of CryoSeal®, an allogeneic single‐donor fibrin sealant, in patients undergoing coronary artery bypass grafting (CABG).</p> </sec> <sec id="bjs9877-sec-0002" sec-type="section"> <title>Methods</title> <p id="bjs9877-para-0002">This randomized clinical study involved seven cardiac surgery centres in the Netherlands. Patients undergoing elective isolated CABG with the use of at least one internal thoracic artery (ITA) graft were assigned randomly to receive either CryoSeal® (5 ml per ITA bed) or no CryoSeal®. Primary efficacy endpoints were units of transfused red blood cells, fresh frozen plasma and platelet concentrates, and duration of intensive care unit stay. Secondary efficacy endpoints were 48‐h blood loss, reoperation for bleeding, mediastinitis, 30‐day mortality and duration of hospital stay.</p> </sec> <sec id="bjs9877-sec-0003" sec-type="section"> <title>Results</title> <p id="bjs9877-para-0003">Between March 2009 and January 2012, 1445 patients were randomized. The intention‐to‐treat (ITT) population comprised 1436 patients; the per‐protocol (PP) population 1292. In both the ITT and the PP analysis, no significant difference between the treatment groups was observed for any of the primary and secondary efficacy endpoints. In addition, no significant difference between the groups was seen in the proportion of transfused patients. Estimated CryoSeal® costs were €822 (95 per cent c.i. €808 to €836) per patient, which translated to €72 000 per avoided transfusion (unbounded 95 per cent c.i.).</p> </sec> <sec id="bjs9877-sec-0004" sec-type="section"> <title>Conclusion</title> <p id="bjs9877-para-0004">The use of the fibrin sealant CryoSeal® did not result in health benefits. Combined with the high cost per avoided transfusion, this study does not support the implementation of routine CryoSeal® use in elective isolated CABG. Registration number: NTR1386 ( <ext-link ext-link-type="uri" xlink:href="http://www.trialregister.nl" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.trialregister.nl</ext-link>).</p> </sec> </abstract>